Persson Frederik, Rossing Peter
Steno Diabetes Center, Gentofte, Denmark.
Ugeskr Laeger. 2012 Sep 10;174(37):2150-4.
Diabetic nephropathy is the leading cause of end stage renal disease in the Western world. 30-35% of the patients with type 2 diabetes will have micro- or macroalbuminuria, warranting yearly screening. Treatment to prevent diabetic nephropathy is multifactorial, adressing known progression promoters such as blood pressure, glycaemia, dyslipidaemia and smoking and includes antithrombotic prophylaxis. Although progress has been made over the last few decades, there is still an unmet need for improved screening, prevention and treatment since both cardiac and renal morbidity and mortality remains severe in this group of patients.
在西方世界,糖尿病肾病是终末期肾病的主要病因。30%至35%的2型糖尿病患者会出现微量或大量白蛋白尿,因此需要每年进行筛查。预防糖尿病肾病的治疗是多方面的,针对已知的病情进展促进因素,如血压、血糖、血脂异常和吸烟等,还包括抗血栓预防。尽管在过去几十年中已取得进展,但由于这类患者的心脏和肾脏发病率及死亡率仍然很高,在改善筛查、预防和治疗方面仍存在未满足的需求。